S-1: A new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer

Isamu Okamoto, Masahiro Fukuoka

研究成果: Contribution to journalReview article査読

24 被引用数 (Scopus)

抄録

S-1 (also known as TS-1; Taiho Pharmaceutical Co. Ltd.; Tokyo, Japan) is a new oral fluoropyrimidine formulation that combines tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate in a molar ratio of 1:0.4:1. Singleagent S-1 has demonstrated marked activity against non-small-cell lung cancer (NSCLC) as well as a broad array of other solid tumors, including gastric, colorectal, breast, cervical, and pancreatic cancers. This comprehensive review summarizes the results of previous clinical studies and describes ongoing clinical trials of S-1 in advanced NSCLC. S-1 combined with platinum compounds, irinotecan, and gemcitabine has produced promising results in terms of feasibility, safety, and effectiveness. Available data have stimulated further research, including phase III trials for the first-line treatment of advanced NSCLC.

本文言語英語
ページ(範囲)290-294
ページ数5
ジャーナルClinical Lung Cancer
10
4
DOI
出版ステータス出版済み - 2009
外部発表はい

All Science Journal Classification (ASJC) codes

  • 腫瘍学
  • 呼吸器内科
  • 癌研究

フィンガープリント

「S-1: A new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル